NADMED, a Finland-based biotechnology company focused on precision measurement of redox metabolites, has established a Scientific Advisory Board (SAB) comprising leading global experts in metabolism, mitochondrial medicine, and clinical diagnostics to guide its next phase of innovation.

Founded in 2022 as a spinout from the University of Helsinki, NADMED has developed the first CE-marked diagnostic platform capable of directly measuring all four nicotinamide adenine dinucleotide (NAD) coenzymes from biological samples, including fresh blood.

The technology aims to address a longstanding gap in understanding mitochondrial dysfunction, altered NAD metabolism, and redox imbalance—factors increasingly linked to neurological disorders, chronic diseases, and rare genetic conditions.

The newly formed SAB will provide strategic direction across research, clinical development, and regulatory pathways as the company scales its diagnostic solutions.

The board is chaired by Charles Brenner, a globally recognized authority on NAD metabolism and Chair in Diabetes & Cancer Metabolism at the Beckman Research Institute, City of Hope. He is joined by Rita Horvath from the University of Cambridge, and Helen Messier, Chief Medical Officer at Bioscope.ai.

“Measuring NAD and related metabolites in blood provides a long-missing connection between basic metabolism and human health. The ability to advance these kits into broad clinical use will open new avenues for understanding disease mechanisms and monitoring interventions,” said Brenner.

Highlighting clinical implications, Horvath added, “Mitochondrial dysfunction is central to many neurological conditions. With accessible and reproducible measurements of redox metabolites, we can begin to evaluate these processes directly in patients in ways that were not previously feasible.”

Messier emphasized the role in precision health: “Precision health depends on biomarkers that can guide individualized care. Reliable measurement of NAD and redox metabolites could enhance how we detect early dysfunction, track interventions, and understand patient variability.”

Jari Närhi, CEO of NADMED, said the SAB will play a critical role in maintaining scientific rigor as the company advances its platform. “We are honored to work with these leaders. Their insights will help ensure that our science meets the highest standards as we collaborate with clinicians and researchers to bring redox biology into routine medical practice.”